David Risinger

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00. In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive...

In a report published Monday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Perrigo Company (NYSE: PRGO), but removed the $167.00 price target. In the report, Morgan Stanley noted, “Double-digit EPS growth looks durable. Perrigo hosted a comprehensive business review and...

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Mylan (NASDAQ: MYL). In the report, Morgan Stanley noted, “MYL's multiple has re-rated; we see a balanced risk-reward ahead of NT binary events. MYL shares are currently trading at 16x our...

In a report published Tuesday, Morgan Stanley analyst David Risinger upgraded the rating on Forest Laboratories (NYSE: FRX) from Equal-Weight to Overweight, and named an $86.00 price target. In the report, Morgan Stanley noted, “Our Base Case is an earnings and multiple call: cons under-estimates...

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Allergan (NYSE: AGN). In the report, Morgan Stanley noted, “Although consensus turned negative in 2013 on DARPin, mgmt is still hopeful that DARPin may offer greater durability (fewer...

According to a report published Monday, Morgan Stanley analyst David Risinger raised the price target on Actavis (NYSE: ACT) following the recent Investor's Day. Risinger believed in the 2014 management being able to achieve the higher end of EPS estimates. CEO Paul Bisaro anticipated several...

In a report published Tuesday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on AbbVie (NYSE: ABBV), but removed the $57.00 price target. In the report, Morgan Stanley noted, “Targacept's (not covered) cognitive deficits in schizophrenia (CDS) drug, TC-5619, failed. This...

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), but removed the $33.00 price target. In the report, Morgan Stanley noted, “We hosted Chuck Triano and Ryan Crowe from Pfizer Investor Relations for lunch in NYC on Thurs. Dec...

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Equal-Weight to Overweight, and raised the price target from $45.00 to $60.00. In the report, Morgan Stanley noted, “Upgrading to OW and raising PT from $45 to $60...

In a report published Monday, Morgan Stanley analyst David Risinger downgraded the rating on Mylan (NASDAQ: MYL) from Overweight to Equal-Weight, and removed the $41.00 price target. In the report, Morgan Stanley noted, “Long-term growth outlook remains robust. We see a compelling pipeline of high...

In a report published Friday, Morgan Stanley analyst David Risinger upgraded the rating on Zoetis (NYSE: ZTS) from Equal-Weight to Overweight, and named a $36.00 price target. In the report, Morgan Stanley noted, “Zoetis is a global leader in animal health, and we expect mgmt. to deliver mid-teens...

In a report published Monday, Morgan Stanley analyst David Risinger downgraded Teva Pharmaceutical (NYSE: TEVA) from Equal-Weight to Underweight, and removed the $40.00 price target. In the report, Morgan Stanley noted, “Earnings face significant pressure in 2014-2017E when Copaxone, Treanda,...

In a report published on Friday, Morgan Stanley analyst David Risinger upgraded Mylan (NASDAQ: MYL) from Equal-weight to Overweight and set a $41 price target. In the report, Morgan Stanley stated, "We are upgrading MYL shares from EW to OW and setting a price target of $41, or 11x 2015E EPS of...

In a report published Wednesday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Teva Pharmaceutical (NYSE: TEVA), but lowered the price target from $42.00 to $40.00. In the report, Morgan Stanley noted, “We are lowering 2014-2017E EPS ests. by 4-13% and PT from $42...